308 related articles for article (PubMed ID: 33131430)
21. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
22. Antivirals that target the host IMPα/β1-virus interface.
Martin AJ; Jans DA
Biochem Soc Trans; 2021 Feb; 49(1):281-295. PubMed ID: 33439253
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
Kinobe RT; Owens L
Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
[TBL] [Abstract][Full Text] [Related]
24. Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529.
Roshni J; Vaishali R; Ganesh KS; Dharani N; Alzahrani KJ; Banjer HJ; Alghamdi AH; Theyab A; Ahmed SS; Patil S
J Infect Public Health; 2022 Jun; 15(6):662-669. PubMed ID: 35617830
[TBL] [Abstract][Full Text] [Related]
25. Elucidation of Teicoplanin Interactions with Drug Targets Related to COVID-19.
Azam F
Antibiotics (Basel); 2021 Jul; 10(7):. PubMed ID: 34356777
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin.
King CR; Tessier TM; Dodge MJ; Weinberg JB; Mymryk JS
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641484
[TBL] [Abstract][Full Text] [Related]
27. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.
Junior NN; Santos IA; Meireles BA; Nicolau MSP; Lapa IR; Aguiar RS; Jardim ACG; José DP
J Biomol Struct Dyn; 2022 Aug; 40(13):5917-5931. PubMed ID: 33478342
[TBL] [Abstract][Full Text] [Related]
28. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids.
Thangavel N; Albratty M
J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
30. Exploration of potent antiviral phytomedicines from Lauraceae family plants against SARS-CoV-2 RNA-dependent RNA polymerase.
Rabaan AA; Halwani MA; Aljeldah M; Al Shammari BR; Garout M; Aldali J; Alawfi A; Alshengeti A; Alsulaiman AM; Alsayyah A
J Biomol Struct Dyn; 2023; 41(24):15085-15105. PubMed ID: 36883874
[TBL] [Abstract][Full Text] [Related]
31. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
Elzupir AO
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
[TBL] [Abstract][Full Text] [Related]
32. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19.
Mujwar S; Sun L; Fidan O
J Food Biochem; 2022 Sep; 46(9):e14219. PubMed ID: 35545850
[TBL] [Abstract][Full Text] [Related]
33. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
[TBL] [Abstract][Full Text] [Related]
35. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
[TBL] [Abstract][Full Text] [Related]
36. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
37. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
Front Immunol; 2021; 12():663586. PubMed ID: 33859652
[TBL] [Abstract][Full Text] [Related]
38. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
39. Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM/GBSA and molecular dynamics simulation.
Azam F; Eid EEM; Almutairi A
J Mol Struct; 2021 Dec; 1246():131124. PubMed ID: 34305175
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
